Abeona Therapeutics to Present at the 28th Annual ROTH

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Abeona Therapeutics to Present at the 28th Annual ROTH Conference

NEW YORK, NY and CLEVELAND, OH  --(Marketwired - March 10, 2016) - Abeona Therapeutics, Inc. ( NASDAQ : ABEO ), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, today announced that President and CEO, Tim Miller, Ph.D., will be presenting an overview of the company at the 28 th Annual Roth Conference on Monday, March 14 th , 2016 at 2pm PST in The Salon 5 PINK Room at The Ritz Carlton in Laguna Nigel, CA.

Event: 28 th Annual ROTH Conference Date: Monday, March 14 th , 2016 Time: 2:00pm PDT Location: The Ritz Carlton in Laguna Nigel, CA. Room: Salon 5 -- PINK Room Webcast Link:  http://wsw.com/webcast/roth30/abeo

  • The presentation will be open to all interested investors through a live audio webcast accessible from http://wsw.com/webcast/roth30/abeo and an archived replay of the webcast will also be available for 90 days following the live presentation.

About ROTH:  ROTH Capital, 28th Annual Conference, is one of the largest of its kind in the U.S. Following the success of previous year's events, the ROTH Conference, with close to 550 participating companies and over 4,000 attendees, will feature presentations from public and private companies in a variety of sectors. This gathering of institutional investors, private equity investors, VCs, company executives and service providers has become a must attend event for anyone working in the small and mid-cap space.

About Abeona :  Abeona Therapeutics, Inc. develops and delivers gene therapy and plasma-based products for severe and life-threatening rare diseases. Abeona's lead programs are ABO-101 (AAV NAGLU) and ABO-102 (AAV SGSH), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (MPS IIIB and IIIA). We are also developing ABO-201 (AAV CLN3) gene therapy for juvenile Batten disease (JBD); and ABO-301 (AAV FANCC) for Fanconi anemia (FA) disorder using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, we are also developing rare plasma protein therapies including SDF Alpha™ (alpha-1 protease inhibitor) for inherited COPD using our proprietary SDF™ (Salt Diafiltration) ethanol-free process. For more information, visit  www.abeonatherapeutics.com .

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include, without limitation, our plans for continued development and internationalization of our clinical programs, management plans for the Company, and general business outlook. These statements are subject to numerous risks and uncertainties, including but not limited to continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.

Company and Media Contact: Andre'a Lucca VP of Communications & Operations Abeona Therapeutics, Inc +1 (212)-786-6208 alucca@abeonatherapeutics.com Magdalena Tyrpien Director of Investor Relations Abeona Therapeutics, Inc. +1 (212)-786-6209 mtyrpien@abeonatherapeutics.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 144

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Lotte's Songdo Plant 1 Puts 120,000 Liters on Deck

Updated Category News Views 95

A 120,000-liter biomanufacturing plant is not a ribbon-cutting trinket; it is a serious industrial bet that has to earn its keep one qualified batch at a time. LOTTE Biologics has completed Plant 1 at its Songdo Bio Campus in Incheon, South Korea, giving the company a sizable new production base as it tries to become a more consequential player in the global CDMO...

Continue Reading
Chaos Zero Nightmare's Award Is a Useful Signal for Games

Updated Category News Views 239

A story award can be easy to sneer at until a live-service game earns one across three markets. Smilegate's Chaos Zero Nightmare, a dark fantasy roguelike RPG developed by Super Creative, was named Best Story in Google Play's Best of 2026 awards for Taiwan, Hong Kong and Macau. That is not a sales figure, not a profit disclosure, and certainly not proof that a hit has...

Continue Reading
Parents Hand Kids Devices Years Before They Intended

Updated Category News Views 286

A nine-year-old with a smartphone used to raise eyebrows; this survey says it is increasingly the household baseline. All About Cookies, working with parental-control company Bark, surveyed U.S. parents and found that children typically receive personal devices well before their parents believe they should. That mismatch is not some cute little parenting contradiction. It...

Continue Reading
BetterInvesting Puts ELMD and FIVE Under a Fresh Lens

Updated Category News Views 74

Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is...

Continue Reading
Kids First Data Sharing Raises Pediatric Research Bar

Updated Category News Views 73

Thirty-eight thousand children’s records are not a headline gimmick; they are a serious argument for treating research data as an asset that must keep working after the first study ends. The Gabriella Miller Kids First Data Resource Center’s ten-year review, published in the September 2026 issue of The American Journal of Human Genetics, makes that argument with...

Continue Reading
Leqembi’s Real-World Data Gives BioArctic More Weight

Updated Category News Views 121

A Harder Look at Treatment Staying Power Alzheimer’s drug data rarely arrive without a thicket of caveats, and that is exactly why this Leqembi update deserves a calm read rather than a victory lap. BioArctic’s partner Eisai presented a three-year real-world analysis at CTAD 2026 covering 560 early Alzheimer’s patients across 13 U.S. sites. The headline is striking:...

Continue Reading
MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 90

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Lake Ridge Sets $0.68 Dividend as 2026 Payouts Rise

Updated Category News Views 96

A community bank raising its cash return is not fireworks, but it gets my attention faster than another glossy growth slogan. Lake Ridge Bancorp has declared a fourth-quarter 2026 dividend of $0.68 per share, payable December 16 to shareholders of record on November 30. That is a plain, useful announcement from OTCQX:LRBI, and plain is often underrated when you are...

Continue Reading
FP Markets Puts Anthropic CFD Into the AI Trading Mix

Updated Category News Views 28

A fresh AI bellwether is about to meet the CFD crowd. FP Markets says it will add an Anthropic share CFD, identified as ANT.xnas, to its lineup on November 19, 2026. Clients worldwide are slated to access it through MetaTrader 5, cTrader, and TradingView. That is a tidy distribution expansion, but it lands with the usual AI-market fireworks already hissing in the...

Continue Reading

Top 5 Most Recently Viewed Articles

Trifork Group Launches 2025 Share-Based Incentive Program

Updated Category News Views 333

Trifork's Innovative Share-Based Incentive Program The Trifork Group AG has taken a significant step towards enhancing employee satisfaction and retention with the introduction of its Share-Based Incentive Program for 2025. This strategic decision supports Trifork’s ongoing commitment to fostering a motivated workforce and aligns with the company’s vision for growth...

Continue Reading
China's Agricultural Modernization: Dezhou's Vital Role

Updated Category News Views 40

Modern Farming Revolution in Dezhou Fifteen years ago, farming technology in Dezhou was a distant dream; today, it's a shining reality. Picture this: Song Zhijie, a veteran farmer, reflecting on a dusty 1997 summer harvest. Now, he sits in air-conditioned cabins, operating state-of-the-art machinery, basking in the efficiency that modern technology has granted. Dezhou, a...

Continue Reading
Exploring the Growth of the Cultured Wheat Market: 2024-2034

Updated Category News Views 142

Exploring the Growth of the Cultured Wheat Market The cultured wheat market is set for remarkable growth, with projections indicating an increase from USD 704.1 million in 2024 to USD 1,273.0 million by 2034. This growth translates to a solid compound annual growth rate (CAGR) of 6.1% over the decade. The rising demand for cultured wheat is driven by several factors,...

Continue Reading
Transforming Urban Mobility: Hikvision's AIoT Innovations

Updated Category News Views 292

Hikvision showcased its game-changing AIoT innovations at the ITS World Congress, zeroing in on making urban mobility safer, smarter, and greener. Their booth was abuzz with tech that’s not just flashy; it’s a serious play aimed at reshaping how we think about transport. The emphasis here? A commitment to road safety that's palpable, with cutting-edge solutions that...

Continue Reading
Avem Health Partners Welcomes Military Veterans to Board of Directors

Updated Category News Views 90

Enhancing Leadership at Avem Health Partners Avem Health Partners, a well-respected hospital management company based in Oklahoma City, is excited to announce the recent appointments of Keith Walker and Barbara Holcomb to its Board of Directors. This strategic decision aims to infuse the organization with a wealth of experience from both military and corporate...

Continue Reading